Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4019-4027

  Gilbert, Christian ^a,c   Azzi, Arezki ^b,d   Goyette, Nathalie ^a   Lin, Sheng Xiang ^b   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d AL IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY IMSIU   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FOSCARNET; GANCICLOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CYTOMEGALOVIRUS; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; DNA-DIRECTED DNA POLYMERASE; FOSCARNET; GANCICLOVIR; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; RECOMBINATION, GENETIC; VIRAL PROTEINS;

EID: 80051817678     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00334-11     Document Type: Article

References (54)

1. Baldanti, F., et al. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395.
2. Baldick, C J, Jr., A. Marchini, C E Patterson, and T. Shenk. 1997. Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J. Virol. 71:4400-4408. (Pubitemid 27204129)
3. Biron, K K, et al. 1985. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 82:2473-2477. (Pubitemid 15071291)
4. Boivin, G., et al. 2001. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with AIDS who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184:1598-1602. (Pubitemid 33139747)
5. Boivin, G., et al. 1997. A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: Longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. AIDS 11:867-873. (Pubitemid 27226409)
6. Boivin, G., N. Goyette, C. Gilbert, A. Humar, and E. Covington. 2005. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis. 7:166-170. (Pubitemid 43015456)
7. Boivin, G., et al. 2004. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189:1615-1618. (Pubitemid 38648289)
8. Boivin, G., et al. 2009. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir. Ther. 14:697-704.
9. Borst, E M, G. Hahn, U H Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: A new approach for construction of HCMV mutants. J. Virol. 73:8320-8329. (Pubitemid 29441693)
10. Cherepanov, P P, and W. Wackernagel. 1995. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158:9-14.
11. Chevillotte, M., I. Ersing, T. Mertens, and J. Von Einem. 2010. Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase. Antimicrob. Agents Chemother. 54:5004-5011.
12. Chevillotte, M., A. Schubert, T. Mertens, and J. Von Einem. 2009. Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother. 53:3752-3761.
13. Chevillotte, M., et al. 2010. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 85:318-327.
14. Chou, S. 2010. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob. Agents Chemother. 54:2371-2378.
15. Chou, S., N S Lurain, K D Thompson, R C Miner, and W L Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39. (Pubitemid 36829739)
16. Chou, S., et al. 1999. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob. Agents Chemother. 43:1500-1502. (Pubitemid 29259354)
17. Chou, S., et al. 2010. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 90:1409-1413.
18. Chou, S., et al. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789. (Pubitemid 27360552)
19. Chou, S, and G I Marousek. 2008. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 82:246-253. (Pubitemid 350309141)
20. Chou, S., G I Marousek, L C Van Wechel, S. Li, and A. Weinberg. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51:4160-4162. (Pubitemid 350057819)
21. Cihlar, T, and M S Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510. (Pubitemid 26425105)
22. Cihlar, T., M D Fuller, and J M Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936. (Pubitemid 28283381)
23. Cihlar, T., M D Fuller, A S Mulato, and J M Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393. (Pubitemid 28417724)
24. Condra, J H 1998. Resistance to HIV protease inhibitors. Haemophilia 4:610-615. (Pubitemid 28351893)
25. Datsenko, K A, and B L Wanner. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645. (Pubitemid 30412767)
26. Ducancelle, A., et al. 2006. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir. Ther. 11:537-540. (Pubitemid 44024862)
27. Erice, A., et al. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092. (Pubitemid 27176495)
28. Gilbert, C, and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883. (Pubitemid 40327699)
29. Gilbert, C, and G. Boivin. 2005. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob. Agents Chemother. 49:4860-4866. (Pubitemid 41778895)
30. Hwang, Y T, B Y Liu, D M Coen, and C B Hwang. 1997. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J. Virol. 71:7791-7798. (Pubitemid 27391725)
31. Jabs, D A, et al. 2001. Longitudinal observations on mutations conferring ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am. J. Ophthalmol. 132:700-710.
32. Kuhn, F J, and C W Knopf. 1996. Herpes simplex virus type 1 DNA polymerase. Mutational analysis of the 3′-5′-exonuclease domain. J. Biol. Chem. 271:29245-29254. (Pubitemid 26382637)
33. Landry, M L, et al. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44:688-692. (Pubitemid 30117962)
34. Limaye, A P, L. Corey, D M Koelle, C L Davis, and M. Boeckh. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649. (Pubitemid 30627592)
35. Limaye, A P, et al. 2002. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185:20-27. (Pubitemid 34043012)
36. Littler, E., A D Stuart, and M S Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
37. Liu, S., et al. 2006. Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 281:18193-18200. (Pubitemid 44035619)
38. Lurain, N S, and S. Chou. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
39. Marchini, A., H. Liu, and H. Zhu. 2001. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75:1870-1878. (Pubitemid 32110177)
40. Martin, M., C. Gilbert, E. Covington, and G. Boivin. 2006. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis. 194:579-583. (Pubitemid 44297841)
41. Martin, M., N. Goyette, and G. Boivin. 2010. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. J. Clin. Virol. 49:296-298.
42. Martin, M., N. Goyette, J. Ives, and G. Boivin. 2010. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J. Clin. Virol. 47:321-324.
43. Mousavi-Jazi, M., et al. 2001. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J. Clin. Virol. 23:1-15. (Pubitemid 32930095)
44. Painter, J, and E A Merritt. 2006. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62:439-450.
45. Parthiban, V., M M Gromiha, and D. Schomburg. 2006. CUPSAT: Prediction of protein stability upon point mutations. Nucleic Acids Res. 34:W239-W242. (Pubitemid 44529771)
46. Piana, S., P. Carloni, and U. Rothlisberger. 2002. Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11:2393-2402.
47. Schreiber, A., et al. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10:191-209.
48. Scott, G M, A. Weinberg, W D Rawlinson, and S. Chou. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51:89-94. (Pubitemid 46047692)
49. Shi, R., A. Azzi, C. Gilbert, G. Boivin, and S X Lin. 2006. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 64:301-307.
50. Smith, I L, et al. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77. (Pubitemid 27272853)
51. Springer, K L, et al. 2005. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus- infected hematopoietic cell transplant recipients. J. Clin. Microbiol. 43:208-213. (Pubitemid 40096302)
52. Sullivan, V., et al. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
53. Turner, D., J M Schapiro, B G Brenner, and M A Wainberg. 2004. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir. Ther. 9:301-314. (Pubitemid 38878746)
54. Weinberg, A., et al. 2003. Mutations conferring foscarnet resistance in a cohort of patients with AIDS and cytomegalovirus retinitis. J. Infect. Dis. 187:777-784. (Pubitemid 36286938)